$56.51
+1.79 (+3.27%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SRRK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 expanded access · 1 with posted results
Held by 15 tracked-famous managers (Holocene Advisors, LP, Qube Research & Technologies Ltd, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, Squarepoint Ops LLC, +10 more) · FINRA short interest 16.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyNCT07047144Evaluate the PK of apitegromab in subjects <2 years old with SMARandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Apitegromab, Nusinersen, Risdiplam | Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin | 52 | Nov 2028 | ≤ 833 d | 2026-05-01 |
| Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDNCT07435129Assess the efficacy of apitegromab compared with placebo in participants with FSHDRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Apitegromab, Placebo | Facioscapulohumeral Muscular Dystrophy, FSHD | 60 | Jun 2028 | ≤ 680 d | 2026-08-11 |
| A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy AdultsNCT07444294Evaluate the safety and tolerability of single and multiple SRK-439 SC dose administration in healthy adult participantsRandomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: Placebo, SRK-439, SRK-439 | Healthy | 76 | 2026-12-17 | in 119 d | 2026-03-02 |
| Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabNCT05626855Evaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMAOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Apitegromab | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin | 238 | 2026-11-01 | in 73 d | 2025-05-25 |
| SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)NCT04291079Safety and tolerability of single agent SRK-181Non-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: SRK-181, anti-PD-(L)1 antibody therapy | Cancer | 112 | 2025-04-14actual | — | 2025-04-29 |
| Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075Change from Baseline in total Lean Body Mass (kg) at 24 weeksRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Apitegromab, Placebo, Tirzepatide | Overweight and Obesity | 102 | 2025-03-04actual | — | 2026-01-23 |
| Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamNCT05156320Main Efficacy Population: Change from Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) total score.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Apitegromab, Placebo | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin | 188 | 2024-12-18actual | — | 2026-01-22 |
| An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular AtrophyNCT03921528results2022-11-17Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12]Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: SRK-015 | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations | 58 | 2021-01-19actual | — | 2024-12-02 |
| EAP of Apitegromab for Patients With Spinal Muscular AtrophyNCT06877689expanded access | — | No longer available | Drug: Apitegromab | SMA | — | — | — | 2026-04-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19